Atopic Dermatitis Clinical Trials Market Report 2026

The atopic dermatitis clinical trials market size has grown rapidly in recent years. It will grow from $2.74 billion in 2025 to $3.07 billion in 2026 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to increasing prevalence of atopic dermatitis, expansion of dermatology-focused drug pipelines, rising clinical research investments, growing participation of CROs in dermatology trials, improvements in trial design methodologies.

The atopic dermatitis clinical trials market size is expected to see rapid growth in the next few years. It will grow to $4.78 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to growing demand for novel biologics and JAK inhibitors, rising adoption of decentralized clinical trials, increasing use of real-world evidence studies, expansion of personalized treatment approaches, increasing regulatory approvals for advanced therapies. Major trends in the forecast period include increasing adoption of biologic and targeted therapies in trials, rising use of digital patient monitoring tools, growing emphasis on patient-centric trial designs, expansion of late-phase multicenter studies, enhanced focus on long-term safety and quality of life endpoints.

The rising pharmaceutical and biopharma investments are expected to drive the growth of the atopic dermatitis clinical trials market going forward. Pharmaceutical and biopharma investments refer to the allocation of funds and capital toward the research, development, production, and commercialization of drugs and biologic therapies. The increase in such investments is driven by the growing demand for innovative therapies, which provide targeted treatment options and improved patient outcomes. Pharmaceutical and biopharma investments support atopic dermatitis clinical trials by financing the research and evaluation of new treatments, enabling scientists to conduct comprehensive studies to verify their safety and efficacy. For instance, in December 2024, according to the Association of Australian Medical Research Institutes (AAMRI), an Australia-based nonprofit organization, Australian medical-research institutes collectively received approximately AUD 2.5 billion (~ USD 1.65 billion) in total revenue in 2023. Therefore, the rising pharmaceutical and biopharma investments are fueling the growth of the atopic dermatitis clinical trials market.

Major companies operating in the atopic dermatitis clinical trials market are focusing on developing innovative therapies, such as oral inhibitors, to maintain consistent therapeutic effects over time. Oral inhibitors are medications administered orally that block specific enzymes or signaling pathways involved in disease progression. For instance, in February 2023, Pfizer Inc., a US-based pharmaceutical and biotechnology company, announced that the US Food and Drug Administration approved its supplemental New Drug Application for CIBINQO (abrocitinib). This approval expanded the drug’s use to adolescents aged 12 to under 18 with moderate-to-severe atopic dermatitis not controlled by other systemic treatments or biologics. Previously, CIBINQO was approved only for adults 18 and older. This expansion provides a new treatment option for younger patients with difficult-to-treat atopic dermatitis, based on clinical trial evidence demonstrating safety and efficacy in this age group.

In May 2024, Johnson & Johnson Services Inc., a US-based multinational pharmaceutical and consumer health company, acquired Yellow Jersey Therapeutics AG for approximately USD 1.25 billion. Through this acquisition, Johnson & Johnson Services Inc. aims to secure global development, manufacturing, and commercialization rights to a novel bispecific antibody, strengthening its immunology and dermatology drug pipeline and accelerating its entry into next-generation treatments for skin disorders. Yellow Jersey Therapeutics AG is a Switzerland-based biotech subsidiary developing the investigational bispecific antibody NM26, a first-in-class therapy targeting IL-4Rα and IL-31, designed to treat atopic dermatitis and related conditions.

Major companies operating in the atopic dermatitis clinical trials market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis International AG, Sanofi S.A., GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Organon & Co., Charles River Laboratories International Inc., LEO Pharma A/S, QIMA Limited, Medpace Holdings Inc., Novotech Health Holdings Pte Ltd., Biocytogen Pharmaceuticals Co. Ltd., REPROCELL Inc., AnaptysBio Inc., Imavita S.A.S., Oncodesign Services S.A.S.

North America was the largest region in the atopic dermatitis clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atopic dermatitis clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atopic dermatitis clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the atopic dermatitis clinical trials market by increasing costs of imported biologics, laboratory reagents, clinical trial supplies, digital monitoring devices, and data management systems used across trial phases. North America and Europe are most affected due to reliance on cross-border supply chains for investigational drugs and trial materials, while Asia-Pacific faces cost pressures in trial site operations. These tariffs are raising overall trial budgets and extending development timelines. However, they are also encouraging regional sourcing of trial supplies, increased collaboration with local CROs, and investment in domestic clinical research infrastructure.

The atopic dermatitis clinical trials market research report is one of a series of new reports that provides atopic dermatitis clinical trials market statistics, including atopic dermatitis clinical trials industry global market size, regional shares, competitors with a atopic dermatitis clinical trials market share, detailed atopic dermatitis clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the atopic dermatitis clinical trials industry. This atopic dermatitis clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Atopic dermatitis clinical trials refer to research studies conducted to evaluate the safety, efficacy, and tolerability of new or existing therapies, including drugs, biologics, and topical agents, for treating atopic dermatitis, a chronic inflammatory skin condition. These trials help advance treatment options by assessing outcomes such as symptom reduction, flare-up frequency, and improvements in quality of life for patients.

The primary phases of atopic dermatitis clinical trials are Phase I, Phase II, Phase III, and Phase IV. Phase I trials are the first human tests of a new treatment, typically involving a small group of participants (around 20-80). These trials are conducted for both small and large molecules and include various study designs such as interventional and observational. They can be delivered through different modes, including outsourced and in-house methods, and are utilized by end users such as contract research organizations (CROs), pharmaceutical and biotechnology companies, and research and academic institutes.

The atopic dermatitis clinical trials market consists of revenues earned by entities by providing services such as preclinical and translational research services, decentralized and virtual trial services, and patient engagement and retention programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The atopic dermatitis clinical trials market also includes sales of topical corticosteroids, oral immunosuppressants, barrier repair creams, and antihistamines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.